Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

Elisabetta Xue, MD, Hu Xie, Wendy Leisenring, ScD, Louise E Kimball, PhD RN, Sonia Goyal, Lisa Chung, Rachel Blazevic, Byron Maltez, Ann Dahlberg, MD, Rachel B. Salit, MD, Colleen Delaney, MD MSc, Steven A. Pergam, MDMPH, Michael Boeckh, MD, Filippo Milano, MD PhD, Joshua Aiden Hill, MD

Blood (2019) 134 (Supplement_1): 4556.

https://doi.org/10.1182/blood-2019-124211

Published: 2019

Journal Articles

Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia

Andreas Engert, MD, Liana Gercheva, MD, PhD, Galina Pilipenko, MD, Tadeusz Robak, MD, PhD, Jingyang Wu, MS, Cynthia A. Sirard, MD, Thomas Elter, MD

Blood (2010) 116 (21): 919.

https://doi.org/10.1182/blood.V116.21.919.919

Published: 2010

Journal Articles

Treatment of Severe Acyclovir-Resistant Herpes Simplex Virus Infection with Continuous Infusion of High Dose Acyclovir Following Hematopoietic Cell Transplantation.

Janet H. Kim, MD, Joanna Schaenman, MD, PhD, Dora Y. Ho, MD, PhD, Janice (Wes) M. Brown, MD

Blood (2009) 114 (22): 2224.

https://doi.org/10.1182/blood.V114.22.2224.2224

Published: 2009

Journal Articles

Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.

Andreas Engert, MD, Liana Gercheva, MD, Tadeusz Robak, Pilipenko Galina, Jingyang Wu, MS, Cynthia A. Sirard, MD, Thomas Elter, MD

Blood (2009) 114 (22): 537.

https://doi.org/10.1182/blood.V114.22.537.537

Published: 2009

Journal Articles

Acyclovir To Prevent Herpes Zoster in Myeloma Patients Treated with Bortezomib.

Eric Vickrey, Sharon Fellingham, Jayesh Mehta, Seema Singhal

Blood (2007) 110 (11): 4807.

https://doi.org/10.1182/blood.V110.11.4807.4807

Published: 2007

Journal Articles

Alemtuzumab (CAMPATH®, MABCAMPATH®) Has Superior Progression Free Survival (PFS) vs Chlorambucil as Front-Line Therapy for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (BCLL).

Peter Hillmen, Aleksander Skotnicki, Tadeusz Robak, Branimir Jaksic, Cynthia Sirard, Jiri Mayer

Blood (2006) 108 (11): 301.

https://doi.org/10.1182/blood.V108.11.301.301

Published: 2006

Journal Articles

Consolidation with Alemtuzumab Improves Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia (CLL) in First Remission - Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

C. Schweighofer, M. Ritgen, B. Eichhorst, R. Busch, M. Kneba, M. Hallek, Clemens Wendtner, the German CLL Study Group

Blood (2006) 108 (11): 33.

https://doi.org/10.1182/blood.V108.11.33.33

Published: 2006

Journal Articles

Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study.

Jennifer R. Brown, MD, Wendy Stock, MD, Harvey I. Katzen, MD, Agustin J. Suarez, MD, Shailendra Lakhanpal, Jose F. Leis, MD, Christopher Flowers, MD, on Behalf of ECO-1 Study Investigators

Blood (2006) 108 (11): 4989.

https://doi.org/10.1182/blood.V108.11.4989.4989

Published: 2006

Journal Articles

Prognostic Factors for CMV Reactivation/Infection after Stem Cell Transplantation and Value of Oral Valganciclovir for Preemptive Therapy.

Thorsten Graef, Tatjana Bobrikova, Ortwin Adams, Roland Fenk, Leilani Ruf, Fabian Zohren, Norbert Gattermann, Rainer Haas, Guido Kobbe

Blood (2005) 106 (11): 5369.

https://doi.org/10.1182/blood.V106.11.5369.5369

Published: 2005

Journal Articles

Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.

Peter Hillmen, MB ChB, PhD, Aleksander B. Skotnicki, MD, PhD, Tadeusz Robak, MD, PhD, Jiri Mayer, MD, PhD, Branimir Jaksic, MD, PhD, Vojo Vukovic, MD, PhD, Steven Weitman, MD, PhD

Blood (2004) 104 (11): 2505.

https://doi.org/10.1182/blood.V104.11.2505.2505

Published: 2004

Journal Articles

Consolidation with Alemtuzumab in First Remission Induces Pronounced MRD Reduction and Clinical Remissions - Update on a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

Matthias Ritgen, MD, C. Schweighofer, MD, Günther Fingerle-Rowson, MD, Barbara Eichhorst, MD, Raimunde Busch, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Michael Kneba, MD, PhD, Michael Hallek, MD, Clemens M. Wendtner, MD

Blood (2004) 104 (11): 2506.

https://doi.org/10.1182/blood.V104.11.2506.2506

Published: 2004

Journal Articles

Campath-1H May Have Activity in the Treatment of Multiple Myeloma.

Cristina Gasparetto, MD, Mitchell E. Horwitz, MD, Jon P. Gockerman, MD, Carlos M. de Castro, MD, Joseph O. Moore, MD, Clay A. Smith, MD, Patty Davis, Martha Lassiter, Lesa Houser, Nelson J. Chao, MD, David Rizzieri, MD

Blood (2004) 104 (11): 4931.

https://doi.org/10.1182/blood.V104.11.4931.4931

Published: 2004

NARROW

High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia

Treatment of Severe Acyclovir-Resistant Herpes Simplex Virus Infection with Continuous Infusion of High Dose Acyclovir Following Hematopoietic Cell Transplantation.

Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.

Acyclovir To Prevent Herpes Zoster in Myeloma Patients Treated with Bortezomib.

Alemtuzumab (CAMPATH®, MABCAMPATH®) Has Superior Progression Free Survival (PFS) vs Chlorambucil as Front-Line Therapy for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (BCLL).

Consolidation with Alemtuzumab Improves Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia (CLL) in First Remission - Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study.

Prognostic Factors for CMV Reactivation/Infection after Stem Cell Transplantation and Value of Oral Valganciclovir for Preemptive Therapy.

Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.

Consolidation with Alemtuzumab in First Remission Induces Pronounced MRD Reduction and Clinical Remissions - Update on a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

Campath-1H May Have Activity in the Treatment of Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only